Precigen/$PGEN
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Precigen
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Ticker
$PGEN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
143
ISIN
US74017N1054
Website
Precigen Metrics
BasicAdvanced
$475M
-
-$0.56
1.82
-
Price and volume
Market cap
$475M
Beta
1.82
52-week high
$2.17
52-week low
$0.65
Average daily volume
1.8M
Financial strength
Current ratio
3.527
Quick ratio
3.39
Long term debt to equity
29.04
Total debt to equity
35.043
Interest coverage (TTM)
-18,578.20%
Profitability
EBITDA (TTM)
-89.331
Gross margin (TTM)
-926.26%
Net profit margin (TTM)
-3,728.87%
Operating margin (TTM)
-2,211.16%
Effective tax rate (TTM)
1.11%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-44.04%
Return on equity (TTM)
-278.55%
Valuation
Price to revenue (TTM)
106.884
Price to book
-33.8
Price to tangible book (TTM)
-12.73
Price to free cash flow (TTM)
-5.966
Free cash flow yield (TTM)
-16.76%
Free cash flow per share (TTM)
-26.99%
Growth
Revenue change (TTM)
-22.76%
Earnings per share change (TTM)
44.55%
3-year revenue growth (CAGR)
-36.42%
10-year revenue growth (CAGR)
-27.01%
3-year earnings per share growth (CAGR)
5.96%
10-year earnings per share growth (CAGR)
-0.33%
What the Analysts think about Precigen
Analyst ratings (Buy, Hold, Sell) for Precigen stock.
Bulls say / Bears say
FDA granted Priority Review to Precigen's Biologics License Application (BLA) for PRGN-2012, with a PDUFA target action date set for August 27, 2025, indicating potential for expedited approval and market entry. (Precigen Press Release)
Precigen completed a $30.9 million public offering in August 2024, bolstering its financial position to support the commercialization of PRGN-2012. (Nasdaq)
Institutional investors, such as LexAurum Advisors LLC, have increased their holdings in Precigen, reflecting confidence in the company's future prospects. (MarketBeat)
Precigen reported a net loss of $126.2 million for the year ended December 31, 2024, compared to a net loss of $95.9 million in the previous year, indicating widening losses. (Precigen Press Release)
The company recorded a $5.8 million impairment charge related to its Exemplar subsidiary in Q4 2024, suggesting challenges in certain business segments. (Precigen Press Release)
Precigen underwent a strategic prioritization, including a reduction of over 20% of its workforce, which may indicate operational challenges and potential disruptions. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Precigen Financial Performance
Revenues and expenses
Precigen Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Precigen stock?
Precigen (PGEN) has a market cap of $475M as of July 04, 2025.
What is the P/E ratio for Precigen stock?
The price to earnings (P/E) ratio for Precigen (PGEN) stock is 0 as of July 04, 2025.
Does Precigen stock pay dividends?
No, Precigen (PGEN) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Precigen dividend payment date?
Precigen (PGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Precigen?
Precigen (PGEN) has a beta rating of 1.82. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.